Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Novel approach reveals metabolic vulnerabilities in kidney cancer

In order to halt the growth of cancer cells, you have to know what feeds them. Researchers at the nationally recognized Kidney Cancer Program at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center have developed a novel approach using glucose that may open up new opportunities for therapeutic intervention.

30 Aug 2018

New approach to assess kidney tumors could prevent patients from undergoing unnecessary surgery

A research team from Roswell Park Comprehensive Cancer Center has discovered a way to use computed tomography imaging to assess kidney tumors that test positive for the biomarker CD117 and accurately determine before surgery, whether the tumor is benign or malignant.

29 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Biomarker predicts kidney cancer risk years before diagnosis

Scientists have identified a blood biomarker that could be used to predict the onset of renal cell carcinoma (RCC) years before the disease is diagnosed.

17 Aug 2018

Blood biomarker could help predict kidney cancer up to five years prior to diagnosis

Every year, more than 330,000 people are diagnosed with kidney cancer worldwide. More than 80 percent of those new cases are renal cell carcinomas.

17 Aug 2018

ZHX2 protein could offer a new treatment strategy for kidney cancer

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change.

20 Jul 2018

Cancer patients receiving anti-PD-1 therapies may experience delayed skin reactions

Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay – sometimes even after treatment has concluded.

19 Jul 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Analysis of lymph node dissection shows no overall survival benefit in renal carcinoma patients

An analysis of lymph node dissection in renal cell carcinoma that has not spread to other organs indicates the procedure is often performed for stage 1 disease and shows no overall survival benefit.

21 May 2018

Depleted metabolic enzymes contribute to tumor growth in renal cancer

Kidney cancer, one of the ten most prevalent malignancies in the world, has increased in incidence over the last decade, likely due to rising obesity rates.

10 May 2018

Non-aspirin NSAID use linked to shorter survival in patients with metastatic renal cell carcinoma

Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs' promising anti-cancer properties have been highlighted by a growing body of data in recent years.

2 May 2018

Study finds link between industry payments and prescription practices for two cancer types

Physicians who received payment from pharmaceutical companies for meals, talks and travel were more likely to prescribe those companies' drugs for two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led study has found.

9 Apr 2018

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center that were reported today in the New England Journal of Medicine.

22 Mar 2018

Oncolytic virus alerts the immune system to attack tumors

A new UC San Francisco study has shown that a cancer-killing virus currently in clinical trials may function as a cancer vaccine - in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus-infected region.

14 Feb 2018

Researchers identify mechanism that regulates signaling events leading to cancer metastasis

Understanding how cancer cells are able to metastasize -- migrate from the primary tumor to distant sites in the body -- and developing therapies to inhibit this process are the focus of many laboratories around the country.

18 Dec 2017

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

New study describes unique role of androgens in kidney cancer

A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.

13 Oct 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

Combination immunotherapy shows better overall survival in kidney cancer patients

A combination immunotherapy treatment showed better overall survival in patients with previously untreated advanced or metastatic renal cell carcinoma than current therapy, according to results from a phase 3 clinical trial presented at the Presidential Symposium of the European Society for Medical Oncology's 2017 Congress in Spain.

13 Sep 2017

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Novel approach reveals metabolic vulnerabilities in kidney cancer

New approach to assess kidney tumors could prevent patients from undergoing unnecessary surgery

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Biomarker predicts kidney cancer risk years before diagnosis

Blood biomarker could help predict kidney cancer up to five years prior to diagnosis

ZHX2 protein could offer a new treatment strategy for kidney cancer

Cancer patients receiving anti-PD-1 therapies may experience delayed skin reactions

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Analysis of lymph node dissection shows no overall survival benefit in renal carcinoma patients

Depleted metabolic enzymes contribute to tumor growth in renal cancer

Non-aspirin NSAID use linked to shorter survival in patients with metastatic renal cell carcinoma

Study finds link between industry payments and prescription practices for two cancer types

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Oncolytic virus alerts the immune system to attack tumors

Researchers identify mechanism that regulates signaling events leading to cancer metastasis

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

New study describes unique role of androgens in kidney cancer

First-ever treatment for Merkel cell carcinoma receives approval in Japan

FDA grants approval for new biosimilar to treat multiple types of cancer

Combination immunotherapy shows better overall survival in kidney cancer patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in